Background: In developing countries, postpartum hemorrhage is responsible for 30% of maternal deaths. Although the World Health Organization recommends use oxytocin prevention hemorrhage, misoprostol increasingly common. The objective this study was to determine frequency in parturients delivering at Saint-Vincent Hospital and compare effectiveness versus preventing hemorrhage. Material Methods...

Misoprostol is a synthetic prostaglandin E1 analogue approved by the Food and Drug Administration (FDA) for the prevention and treatment of gastroduodenal ulcers. Norman et al. first demonstrated its uterocontractive abortifacient properties in 19911. This publication generated great interest in the search for the potential uses of misoprostol in Obstetrics and Gynecology. Misoprostol has since...

BACKGROUND Postpartum hemorrhage (PPH) is a leading cause of maternal death in sub-Saharan Africa. Although the World Health Organization recommends use of oxytocin for prevention of PPH, misoprostol use is increasingly common owing to advantages in shelf life and potential for sublingual administration. There is a lack of data about the comparative efficacy of oxytocin and sublingual misoprost...

As a stable, orally active and cheap uterotonic, misoprostol would appear ideally suited to the prevention of postpartum hemorrhage (PPH) in the developing world. Following numerous clinical trials, it appears that misoprostol prophylaxis using an oral or sublingual dose of 600 microg is more effective than placebo at preventing PPH in community births (relative risk 0.59, 95% confidence interv...

BACKGROUND Termination of pregnancy in the second trimester using prostaglandins has been shown to be safe and effective. Misoprostol has multiple routes of administration; oral, vaginal, buccal, rectal and sublingual. OBJECTIVE The study aims to compare the efficacy and safety of intrauterine extra-amniotic and vaginal misoprostol in a dose of 200 microgram every 4 hours for the termination ...

OBJECTIVE To investigate whether use of preoperative misoprostol can reduce blood loss during total abdominal hysterectomy (TAH). METHODS In a randomized double-blind placebo-controlled trial at a tertiary care hospital in Kolkata, India, between March 2011 and April 2012, women (n=132) undergoing TAH with or without bilateral salpingo-oophorectomy for symptomatic myomas were randomly allocat...

Background: Current study was conducted to compare the efficacy of tab Misoprostol 50 microgram by oral and sublingual routes for induction labour. Methods: A randomised comparative labour in 200 cases pregnant women at term were divided into two groups 100 each µg route repeated 4 hourly either or until an adequate contraction pattern set (establishment 3 uterine contractions a period 10 minut...